» Articles » PMID: 39172054

Expression of MAF BZIP Transcription Factor B Protects Against Ulcerative Colitis Through the Inhibition of the NF-κB Pathway

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of this study was to explore whether MAF bZIP transcription factor B (MAFB) might alleviate ulcerative colitis (UC) in dextran sulfate sodium (DSS)-induced mice and LPS-induced IEC-6 cells.

Methods: UC in vivo and in vitro model was established by using DSS and LPS, respectively. The mice body weight and disease activity index (DAI) score were recorded daily, and colon length was measured. Moreover, the permeability was evaluated utilizing a fluorescein isothiocyanate dextran (FITC-Dextran) probe. Histopathological changes of DSS-induced colitis mice was assessed utilizing H&E staining. Next, qRT-PCR was performed to detect IL-1β, IL-6, TNF-α, and IL-10 level in in vivo and in vitro. Furthermore, the level of MDA, SOD, CAT, and GSH were evaluated in colon tissues. Besides, the expressions of tight junction proteins and NF-κB pathway relative proteins were examined in colitis mice and IEC-6 cells using western blot, immunohistochemistry and immunofluorescence.

Results: MAFB level was downregulated in DSS-induced colitis mice. Moreover, the upregulation of MAFB protected mice from DSS-induced colitis by suppressing DSS-induced inflammation, oxidative stress, and intestinal barrier impairment. We also demonstrated that the upregulation of MAFB inactivated NF-κB pathway in DSS-caused colitis mice. Subsequently, we observed that MAFB upregulation could inhibit LPS-caused epithelial barrier impairment and inflammation in IEC-6 cells. Additionally, MAFB overexpression could suppress the activation of NF-κB pathway in IEC-6 cells.

Conclusion: The upregulation of MAFB could protect against UC via the suppression of inflammation and the intestinal barrier impairment through inhibiting the NF-κB pathway.

Citing Articles

Expression of MAF bZIP transcription factor B protects against ulcerative colitis through the inhibition of the NF-κB pathway.

Li J, Li Q, Ma W, Zhang Y, Li X Immun Inflamm Dis. 2024; 12(8):e1372.

PMID: 39172054 PMC: 11340633. DOI: 10.1002/iid3.1372.

References
1.
Peng L, Gao X, Nie L, Xie J, Dai T, Shi C . Astragalin Attenuates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis by Alleviating Gut Microbiota Dysbiosis and Inhibiting NF-κB Activation in Mice. Front Immunol. 2020; 11:2058. PMC: 7523281. DOI: 10.3389/fimmu.2020.02058. View

2.
Hamada M, Tsunakawa Y, Jeon H, Yadav M, Takahashi S . Role of MafB in macrophages. Exp Anim. 2019; 69(1):1-10. PMC: 7004803. DOI: 10.1538/expanim.19-0076. View

3.
Bing X, Xuelei L, Wanwei D, Linlang L, Keyan C . EGCG Maintains Th1/Th2 Balance and Mitigates Ulcerative Colitis Induced by Dextran Sulfate Sodium through TLR4/MyD88/NF-B Signaling Pathway in Rats. Can J Gastroenterol Hepatol. 2018; 2017:3057268. PMC: 5748319. DOI: 10.1155/2017/3057268. View

4.
Iskandar H, Dhere T, Farraye F . Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015; 17(11):44. DOI: 10.1007/s11894-015-0466-9. View

5.
Yang J, Pei G, Sun X, Xiao Y, Miao C, Zhou L . RhoB affects colitis through modulating cell signaling and intestinal microbiome. Microbiome. 2022; 10(1):149. PMC: 9482252. DOI: 10.1186/s40168-022-01347-3. View